Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Q3 earnings expectations and the first full quarter of Northern Data/Quake AI revenue dominate discussion, with traders weighing acquisition-driven growth against questions about margins, cash needs, and potential dilution. Some also point to elevated short interest as possible squeeze fuel, while others remain skeptical about execution and the reported Anthropic arrangement.

CoreWeaves quarterly revenue beat and raised outlook, alongside strong AI-compute demand and a plan to rely more on customer prepayments and secured financing, have fueled a bullish rebound and short-squeeze speculation. Traders remain divided: supporters see the results easing funding concerns, while skeptics point to heavy debt, interest costs, capital spending and uncertain profitability.

Rigettis quarterly results missed expectations and its 2026 revenue outlook fell short, fueling concerns about its valuation and how long commercialization may take. Bulls point to quantum-hardware progress and government support, while skeptics question whether those milestones will translate into paying customers and repeat revenue.

Nvidias sharp selloff and volatile rebound are centered on scrutiny of CEO Jensen Huang over allegations tied to China chip shipments, alongside a Baird downgrade. Traders disagree on whether the controversy and potential investigations threaten the company, while bullish voices argue AI demand remains strong, pointing to CoreWeaves results and Nvidias upcoming earnings as counterpoints.

Ousters quarterly results, including strong revenue and sensor-shipment growth, have focused attention on demand for its lidar and Stereolabs cameras across robotics and other Physical AI applications. Traders are mostly upbeat about the operating momentum, but debate the outlook and margin pressure, while some attribute the volatile share-price reaction to broader weakness in AI and growth stocks.

SOXX is drawing attention amid sharp semiconductor volatility as traders debate whether the AI-driven selloff is overdone or signals weaker data-center spending and tougher project economics. Bulls point to continued chip demand and view the rebound as a buying opportunity, while bears cite damaged technicals and lingering uncertainty, including Nvidia-related headlines.

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with the company reaffirming confidence in the therapy and saying its application is in final review ahead of the November 22 target date. Many traders read managements comments and launch preparations as encouraging, while others warn that approval is uncertain given the FDAs prior concerns and the binary regulatory risk.

Costcos announcement of a record special dividend and renewed share-buyback authorization is driving attention, with many traders welcoming the shareholder payout. Others argue the stock remains expensive and caution that the dividend is not free value to shareholders.

Amentums recent defense, nuclear and NASA contract wins are drawing attention, but traders are frustrated that the awards have not translated into sustained share-price strength. The community is split between viewing the growing contract backlog and low valuation as a long-term opportunity and questioning the companys growth, margins, debt and management.

Earnings anticipation is driving attention, with traders focused on whether AI-infrastructure networking orders translate into durable revenue and cash flow, and whether inventory growth and margin pressure temper the opportunity. Some expect strong results and guidance, while skeptics question the durability and funding of AI demand.